Brief: Abbisko Cayman Says CSF-1R Inhibitor Pimicotinib Granted Priority Medicine Designation
07/06/2023 15:46
June 7 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR PIMICOTINIB GRANTED PRIORITY MEDICINE
DESIGNATION BY EUROPEAN MEDICINES AGENCY
Source text for Eikon: ID:
Further company coverage: 2256.HK
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly